Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2019

Open Access 01-12-2019 | Ulcerative Colitis | Review

Integrating omics for a better understanding of Inflammatory Bowel Disease: a step towards personalized medicine

Authors: Manoj Kumar, Mathieu Garand, Souhaila Al Khodor

Published in: Journal of Translational Medicine | Issue 1/2019

Login to get access

Abstract

Background

Inflammatory Bowel Disease (IBD) is a multifactorial chronic disease. Understanding only one aspect of IBD pathogenesis does not reflect the complex nature of IBD nor will it improve its clinical management. Therefore, it is vital to dissect the interactions between the different players in IBD pathogenesis in order to understand the biology of the disease and enhance its clinical outcomes.

Aims

To provide an overview of the available omics data used to assess the potential mechanisms through which various players are contributing to IBD pathogenesis and propose a precision medicine model to fill the current knowledge gap in IBD.

Results

Several studies have reported microbial dysbiosis, immune and metabolic dysregulation in IBD patients, however, this data is not sufficient to create signatures that can differentiate between the disease subtypes or between disease relapse and remission.

Conclusions

We summarized the current knowledge in the application of omics in IBD patients, and we showed that the current knowledge gap in IBD hinders the improvements of clinical decision for treatment as well as the prediction of disease relapse. We propose one way to fill this gap by implementing integrative analysis of various omics datasets generated from one patient at a single time point.
Literature
1.
Mehta M, Ahmed S, Dryden G. Immunopathophysiology of inflammatory bowel disease: how genetics link barrier dysfunction and innate immunity to inflammation. Innate Immun. 2017;23:497–505.PubMedCrossRef
2.
3.
Rieder F, Fiocchi C. Intestinal fibrosis in IBD—a dynamic, multifactorial process. Nat Rev Gastroenterol Hepatol. 2009;6:228–35.PubMedCrossRef
4.
Yu YR, Rodriguez JR. Clinical presentation of Crohn’s, ulcerative colitis, and indeterminate colitis: symptoms, extraintestinal manifestations, and disease phenotypes. Semin Pediatr Surg. 2017;26:349–55.PubMedCrossRef
5.
Feakins RM. Ulcerative colitis or Crohn’s disease? Pitfalls and problems. Histopathology. 2014;64:317–35.PubMedCrossRef
6.
Tontini GE, Vecchi M, Pastorelli L, et al. Differential diagnosis in inflammatory bowel disease colitis: state of the art and future perspectives. World J Gastroenterol. 2015;21:21–46.PubMedPubMedCentralCrossRef
7.
Monteiro S, Dias de Castro F, Boal Carvalho P, et al. Essential role of small bowel capsule endoscopy in reclassification of colonic inflammatory bowel disease type unclassified. World J Gastrointest Endosc. 2017;9:34–40.PubMedPubMedCentralCrossRef
8.
9.
Samuel Wilks WM. Lectures on pathological anatomy: Lindsay and Blakiston. 1875.
10.
11.
Kim HJ, Hann HJ, Hong SN, et al. Incidence and natural course of inflammatory bowel disease in Korea, 2006–2012: a nationwide population-based study. Inflamm Bowel Dis. 2015;21:623–30.PubMedCrossRef
12.
Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46–54.e42 (quiz e30).PubMedCrossRef
13.
Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12:720–7.PubMedCrossRef
14.
Sykora J, Pomahacova R, Kreslova M, et al. Current global trends in the incidence of pediatric-onset inflammatory bowel disease. World J Gastroenterol. 2018;24:2741–63.PubMedPubMedCentralCrossRef
15.
Marchesi JR, Adams DH, Fava F, et al. The gut microbiota and host health: a new clinical frontier. Gut. 2016;65:330–9.PubMedCrossRef
16.
Imhann F, Vich Vila A, Bonder MJ, et al. Interplay of host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory bowel disease. Gut. 2018;67:108–19.PubMedCrossRef
17.
Weersma RK, Xavier RJ, Consortium IBDMO, et al. Multiomics analyses to deliver the most effective treatment to every patient with inflammatory bowel disease. Gastroenterology. 2018;155:e1–4.PubMedCrossRef
18.
19.
Levine A, Koletzko S, Turner D, et al. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr. 2014;58:795–806.PubMed
20.
Xu XR, Liu CQ, Feng BS, et al. Dysregulation of mucosal immune response in pathogenesis of inflammatory bowel disease. World J Gastroenterol. 2014;20:3255–64.PubMedPubMedCentralCrossRef
21.
22.
23.
Tharian B, George N, Navaneethan U. Endoscopy in the diagnosis and management of complications of inflammatory bowel disease. Inflamm Bowel Dis. 2016;22:1184–97.PubMedCrossRef
24.
Taylor S, Lobo AJ. Diagnosis and treatment of inflammatory bowel disease. Practitioner. 2016;260:19–23.PubMed
25.
Padoan A, D’Inca R, Scapellato ML, et al. Improving IBD diagnosis and monitoring by understanding preanalytical, analytical and biological fecal calprotectin variability. Clin Chem Lab Med. 2018;56:1926–35.PubMedCrossRef
26.
Koksal AR, Boga S, Alkim H, et al. How does a biopsy of endoscopically normal terminal ileum contribute to the diagnosis? Which patients should undergo biopsy? Libyan J Med. 2014;9:23441.PubMedCrossRef
27.
Magro F, Langner C, Driessen A, et al. European consensus on the histopathology of inflammatory bowel disease. J Crohns Colitis. 2013;7:827–51.PubMedCrossRef
28.
Surawicz CM, Haggitt RC, Husseman M, et al. Mucosal biopsy diagnosis of colitis: acute self-limited colitis and idiopathic inflammatory bowel disease. Gastroenterology. 1994;107:755–63.PubMedCrossRef
29.
Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis. 2011;17:1314–21.PubMedCrossRef
30.
Kornbluth A, Sachar DB, Practice Parameters Committee of the American College of G. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2004;99:1371–85.PubMedCrossRef
31.
Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG clinical guideline: management of Crohn’s disease in adults. Am J Gastroenterol. 2018;113:481–517.PubMedCrossRef
32.
Bartunkova J, Kolarova I, Sediva A, et al. Antineutrophil cytoplasmic antibodies, anti-Saccharomyces cerevisiae antibodies, and specific IgE to food allergens in children with inflammatory bowel diseases. Clin Immunol. 2002;102:162–8.PubMedCrossRef
33.
Matsui T, Yao T, Sakurai T, et al. Clinical features and pattern of indeterminate colitis: Crohn’s disease with ulcerative colitis-like clinical presentation. J Gastroenterol. 2003;38:647–55.PubMedCrossRef
34.
Franke A, McGovern DP, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci. Nat Genet. 2010;42:1118–25.PubMedPubMedCentralCrossRef
35.
36.
Shaw KA, Cutler DJ, Okou D, et al. Genetic variants and pathways implicated in a pediatric inflammatory bowel disease cohort. Genes Immun. 2019;20:131–42.PubMedCrossRef
37.
Homer CR, Richmond AL, Rebert NA, et al. ATG16L1 and NOD2 interact in an autophagy-dependent antibacterial pathway implicated in Crohn’s disease pathogenesis. Gastroenterology. 2010;139:1630–41, 1641 e1–2.CrossRef
38.
Wellcome Trust Case Control C. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447:661–78.CrossRef
39.
40.
Althani AA, Marei HE, Hamdi WS, et al. Human microbiome and its association with health and diseases. J Cell Physiol. 2016;231:1688–94.PubMedCrossRef
41.
Human Microbiome Project C. Structure, function and diversity of the healthy human microbiome. Nature. 2012;486:207–14.CrossRef
42.
Singh P, Kumar M, Al Khodor S. Vitamin D deficiency in the gulf cooperation council: exploring the triad of genetic predisposition, the gut microbiome and the immune system. Front Immunol. 2019;10:1042.PubMedPubMedCentralCrossRef
43.
44.
Lederberg J, McCray AT. ‘Ome Sweet’ omics—a genealogical treasury of words. Scientist. 2001;15:8.
45.
Gupta VK, Paul S, Dutta C. Geography, ethnicity or subsistence-specific variations in human microbiome composition and diversity. Front Microbiol. 2017;8:1162.PubMedPubMedCentralCrossRef
46.
Barko PC, McMichael MA, Swanson KS, et al. The gastrointestinal microbiome: a review. J Vet Intern Med. 2018;32:9–25.PubMedCrossRef
47.
48.
Hoffmann C, Dollive S, Grunberg S, et al. Archaea and fungi of the human gut microbiome: correlations with diet and bacterial residents. PLoS ONE. 2013;8:e66019.PubMedPubMedCentralCrossRef
49.
50.
51.
Sirisinha S. The potential impact of gut microbiota on your health: current status and future challenges. Asian Pac J Allergy Immunol. 2016;34:249–64.PubMed
52.
Weiss GA, Hennet T. Mechanisms and consequences of intestinal dysbiosis. Cell Mol Life Sci. 2017;74:2959–77.PubMedCrossRef
53.
Peng J, Xiao X, Hu M, et al. Interaction between gut microbiome and cardiovascular disease. Life Sci. 2018;214:153–7.PubMedCrossRef
54.
Mangiola F, Nicoletti A, Gasbarrini A, et al. Gut microbiota and aging. Eur Rev Med Pharmacol Sci. 2018;22:7404–13.PubMed
55.
Liu J, Wu M, He J, et al. Antibiotic-induced dysbiosis of gut microbiota impairs corneal nerve regeneration by affecting CCR2-negative macrophage distribution. Am J Pathol. 2018;188:2786–99.PubMedPubMedCentralCrossRef
56.
Li N, Wang Q, Wang Y, et al. Oral probiotics ameliorate the behavioral deficits induced by chronic mild stress in mice via the gut microbiota-inflammation axis. Front Behav Neurosci. 2018;12:266.PubMedPubMedCentralCrossRef
57.
58.
Joossens M, Faust K, Gryp T, et al. Gut microbiota dynamics and uraemic toxins: one size does not fit all. Gut. 2019;68:2257–60.PubMedCrossRef
59.
Bell JS, Spencer JI, Yates RL, et al. From nose to gut—the role of the microbiome in neurological disease. Neuropathol Appl Neurobiol. 2018.
60.
61.
Dickson I. Gut microbiota: diagnosing IBD with the gut microbiome. Nat Rev Gastroenterol Hepatol. 2017;14:195.PubMedCrossRef
62.
Flint HJ, Scott KP, Louis P, et al. The role of the gut microbiota in nutrition and health. Nat Rev Gastroenterol Hepatol. 2012;9:577–89.PubMedCrossRef
63.
Al Khodor S, Shatat IF. Gut microbiome and kidney disease: a bidirectional relationship. Pediatr Nephrol. 2017;32:921–31.PubMedCrossRef
64.
65.
66.
Qin Y, Roberts JD, Grimm SA, et al. An obesity-associated gut microbiome reprograms the intestinal epigenome and leads to altered colonic gene expression. Genome Biol. 2018;19:7.PubMedPubMedCentralCrossRef
67.
Murugesan S, Nirmalkar K, Hoyo-Vadillo C, et al. Gut microbiome production of short-chain fatty acids and obesity in children. Eur J Clin Microbiol Infect Dis. 2018;37:621–5.PubMedCrossRef
68.
Luo Y, Blackledge WC. Microbiome-based mechanisms hypothesized to initiate obesity-associated rheumatoid arthritis. Obes Rev. 2018;19:786–97.PubMedCrossRef
69.
Leong KSW, Derraik JGB, Hofman PL, et al. Antibiotics, gut microbiome and obesity. Clin Endocrinol. 2018;88:185–200.CrossRef
70.
Langan EA, Gratz V, Billmann F, et al. Does the gastrointestinal microbiome contribute to the ‘obesity paradox’ in melanoma survival? Br J Dermatol. 2018;179:225–6.PubMedCrossRef
71.
Cheng M, Zhang X, Zhu J, et al. A metagenomics approach to the intestinal microbiome structure and function in high fat diet-induced obesity mice fed with oolong tea polyphenols. Food Funct. 2018;9:1079–87.PubMedCrossRef
72.
Castaner O, Goday A, Park YM, et al. The gut microbiome profile in obesity: a systematic review. Int J Endocrinol. 2018;2018:4095789.PubMedPubMedCentral
73.
Fedorak RN, Ismond KP. Practical considerations and the intestinal microbiome in disease: antibiotics for IBD therapy. Dig Dis. 2016;34:112–21.PubMedCrossRef
74.
Hansen JJ, Sartor RB. Therapeutic manipulation of the microbiome in IBD: current results and future approaches. Curr Treat Options Gastroenterol. 2015;13:105–20.PubMedPubMedCentralCrossRef
75.
Lavelle A, Sokol H. Gut microbiota: beyond metagenomics, metatranscriptomics illuminates microbiome functionality in IBD. Nat Rev Gastroenterol Hepatol. 2018;15:193–4.PubMedCrossRef
76.
Rehman A, Rausch P, Wang J, et al. Geographical patterns of the standing and active human gut microbiome in health and IBD. Gut. 2016;65:238–48.PubMedCrossRef
77.
Santoru ML, Piras C, Murgia A, et al. Cross sectional evaluation of the gut-microbiome metabolome axis in an Italian cohort of IBD patients. Sci Rep. 2017;7:9523.PubMedPubMedCentralCrossRef
78.
Sitkin S, Vakhitov T, Pokrotnieks J. How to increase the butyrate-producing capacity of the gut microbiome: do IBD patients really need butyrate replacement and butyrogenic therapy? J Crohns Colitis. 2018;12:881–2.PubMedCrossRef
79.
Wu GD. Diet, the gut microbiome and the metabolome in IBD. Nestle Nutr Inst Workshop Ser. 2014;79:73–82.PubMedCrossRef
80.
Kumar M, Mathur T, Joshi V, et al. Effect of DS-2969b, a novel GyrB inhibitor, on rat and monkey intestinal microbiota. Anaerobe. 2018;51:120–3.PubMedCrossRef
81.
Martinez-Medina M, Garcia-Gil LJ. Escherichia coli in chronic inflammatory bowel diseases: an update on adherent invasive Escherichia coli pathogenicity. World J Gastrointest Pathophysiol. 2014;5:213–27.PubMedPubMedCentralCrossRef
82.
Lopez-Siles M, Martinez-Medina M, Busquets D, et al. Mucosa-associated Faecalibacterium prausnitzii and Escherichia coli co-abundance can distinguish Irritable Bowel Syndrome and Inflammatory Bowel Disease phenotypes. Int J Med Microbiol. 2014;304:464–75.PubMedCrossRef
83.
Takahashi K, Nishida A, Fujimoto T, et al. Reduced abundance of butyrate-producing bacteria species in the fecal microbial community in Crohn’s disease. Digestion. 2016;93:59–65.CrossRefPubMed
84.
Machiels K, Joossens M, Sabino J, et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut. 2014;63:1275–83.CrossRefPubMed
85.
Willing BP, Dicksved J, Halfvarson J, et al. A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterology. 2010;139(1844–1854):e1.
86.
Conte MP, Longhi C, Marazzato M, et al. Adherent-invasive Escherichia coli (AIEC) in pediatric Crohn’s disease patients: phenotypic and genetic pathogenic features. BMC Res Notes. 2014;7:748.PubMedPubMedCentralCrossRef
87.
Man SM, Zhang L, Day AS, et al. Campylobacter concisus and other Campylobacter species in children with newly diagnosed Crohn’s disease. Inflamm Bowel Dis. 2010;16:1008–16.PubMedCrossRef
88.
Rowan F, Docherty NG, Murphy M, et al. Desulfovibrio bacterial species are increased in ulcerative colitis. Dis Colon Rectum. 2010;53:1530–6.PubMedCrossRef
89.
Negroni A, Costanzo M, Vitali R, et al. Characterization of adherent-invasive Escherichia coli isolated from pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:913–24.PubMedCrossRef
90.
Campos N, Magro F, Castro AR, et al. Macrophages from IBD patients exhibit defective tumour necrosis factor-alpha secretion but otherwise normal or augmented pro-inflammatory responses to infection. Immunobiology. 2011;216:961–70.PubMedCrossRef
91.
Sasaki M, Sitaraman SV, Babbin BA, et al. Invasive Escherichia coli are a feature of Crohn’s disease. Lab Investig. 2007;87:1042–54.PubMedCrossRef
92.
Zhang S, Fu J, Dogan B, et al. 5-Aminosalicylic acid downregulates the growth and virulence of Escherichia coli associated with IBD and colorectal cancer, and upregulates host anti-inflammatory activity. J Antibiot. 2018;71:950–61.CrossRef
93.
Renouf MJ, Cho YH, McPhee JB. Emergent behavior of IBD-associated Escherichia coli during disease. Inflamm Bowel Dis. 2019;25(1):33–44.PubMedCrossRef
94.
Ummarino D. Spondyloarthropathies: E. coli links IBD to spondyloarthritis. Nat Rev Rheumatol. 2017;13:198.PubMedCrossRef
95.
Kotlowski R. Use of Escherichia coli Nissle 1917 producing recombinant colicins for treatment of IBD patients. Med Hypotheses. 2016;93:8–10.PubMedCrossRef
96.
Bucker R, Schulz E, Gunzel D, et al. alpha-Haemolysin of Escherichia coli in IBD: a potentiator of inflammatory activity in the colon. Gut. 2014;63:1893–901.PubMedCrossRef
97.
Ray K. IBD: fertilizing the gut: host-derived nitrate contributes to Escherichia coli bloom in colitis. Nat Rev Gastroenterol Hepatol. 2013;10:197.PubMedCrossRef
98.
Darfeuille-Michaud A, Colombel JF. Pathogenic Escherichia coli in inflammatory bowel diseases: proceedings of the 1st international meeting on E. coli and IBD, June 2007, Lille, France. J Crohns Colitis. 2008;2:255–62.PubMedCrossRef
99.
La Ferla K, Seegert D, Schreiber S. Activation of NF-kappaB in intestinal epithelial cells by E. coli strains isolated from the colonic mucosa of IBD patients. Int J Colorectal Dis. 2004;19:334–42.PubMedCrossRef
100.
O’Brien CL, Bringer MA, Holt KE, et al. Comparative genomics of Crohn’s disease-associated adherent-invasive Escherichia coli. Gut. 2017;66:1382–9.PubMedCrossRef
101.
Zhang Y, Rowehl L, Krumsiek JM, et al. Identification of candidate adherent-invasive E. coli signature transcripts by genomic/transcriptomic analysis. PLoS ONE. 2015;10:e0130902.PubMedPubMedCentralCrossRef
102.
Borruel N, Carol M, Casellas F, et al. Increased mucosal tumour necrosis factor alpha production in Crohn’s disease can be downregulated ex vivo by probiotic bacteria. Gut. 2002;51:659–64.PubMedPubMedCentralCrossRef
103.
Glasser AL, Boudeau J, Barnich N, et al. Adherent invasive Escherichia coli strains from patients with Crohn’s disease survive and replicate within macrophages without inducing host cell death. Infect Immun. 2001;69:5529–37.PubMedPubMedCentralCrossRef
104.
Wagner J, Short K, Catto-Smith AG, et al. Identification and characterisation of Pseudomonas 16S ribosomal DNA from ileal biopsies of children with Crohn’s disease. PLoS ONE. 2008;3:e3578.PubMedPubMedCentralCrossRef
105.
Wei B, Huang T, Dalwadi H, et al. Pseudomonas fluorescens encodes the Crohn’s disease-associated I2 sequence and T-cell superantigen. Infect Immun. 2002;70:6567–75.PubMedPubMedCentralCrossRef
106.
Horing E, Gopfert D, Schroter G, et al. Frequency and spectrum of microorganisms isolated from biopsy specimens in chronic colitis. Endoscopy. 1991;23:325–7.PubMedCrossRef
107.
Mottawea W, Chiang CK, Muhlbauer M, et al. Altered intestinal microbiota-host mitochondria crosstalk in new onset Crohn’s disease. Nat Commun. 2016;7:13419.PubMedPubMedCentralCrossRef
108.
Bashir A, Miskeen AY, Hazari YM, et al. Fusobacterium nucleatum, inflammation, and immunity: the fire within human gut. Tumour Biol. 2016;37:2805–10.PubMedCrossRef
109.
Strauss J, Kaplan GG, Beck PL, et al. Invasive potential of gut mucosa-derived Fusobacterium nucleatum positively correlates with IBD status of the host. Inflamm Bowel Dis. 2011;17:1971–8.PubMedCrossRef
110.
111.
Alipour M, Zaidi D, Valcheva R, et al. Mucosal barrier depletion and loss of bacterial diversity are primary abnormalities in paediatric ulcerative colitis. J Crohns Colitis. 2016;10:462–71.PubMedCrossRef
112.
Cader MZ, Kaser A. Recent advances in inflammatory bowel disease: mucosal immune cells in intestinal inflammation. Gut. 2013;62:1653–64.PubMedCrossRef
113.
Gordon HA. Morphological and physiological characterization of germfree life. Ann N Y Acad Sci. 1959;78:208–20.PubMedCrossRef
114.
115.
Martini E, Krug SM, Siegmund B, et al. Mend your fences: the epithelial barrier and its relationship with mucosal immunity in inflammatory bowel disease. Cell Mol Gastroenterol Hepatol. 2017;4:33–46.PubMedPubMedCentralCrossRef
116.
Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119–24.PubMedPubMedCentralCrossRef
117.
Kang S, Denman SE, Morrison M, et al. Dysbiosis of fecal microbiota in Crohn’s disease patients as revealed by a custom phylogenetic microarray. Inflamm Bowel Dis. 2010;16:2034–42.PubMedCrossRef
118.
119.
Pascal V, Pozuelo M, Borruel N, et al. A microbial signature for Crohn’s disease. Gut. 2017;66:813–22.PubMedCrossRef
120.
121.
Franzosa EA, Sirota-Madi A, Avila-Pacheco J, et al. Gut microbiome structure and metabolic activity in inflammatory bowel disease. Nat Microbiol. 2019;4:293–305.PubMedCrossRef
122.
Moustafa A, Li W, Anderson EL, et al. Genetic risk, dysbiosis, and treatment stratification using host genome and gut microbiome in inflammatory bowel disease. Clin Transl Gastroenterol. 2018;9:e132.PubMedPubMedCentralCrossRef
123.
Papa E, Docktor M, Smillie C, et al. Non-invasive mapping of the gastrointestinal microbiota identifies children with inflammatory bowel disease. PLoS ONE. 2012;7:e39242.PubMedPubMedCentralCrossRef
124.
Lewis JD, Chen EZ, Baldassano RN, et al. Inflammation, antibiotics, and diet as environmental stressors of the gut microbiome in pediatric Crohn’s disease. Cell Host Microbe. 2015;18:489–500.PubMedPubMedCentralCrossRef
125.
de Souza HSP, Fiocchi C, Iliopoulos D. The IBD interactome: an integrated view of aetiology, pathogenesis and therapy. Nat Rev Gastroenterol Hepatol. 2017;14:739–49.PubMedCrossRef
126.
Lloyd-Price J, Arze C, Ananthakrishnan AN, et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature. 2019;569:655–62.PubMedPubMedCentralCrossRef
127.
128.
129.
130.
131.
Wagner J, Maksimovic J, Farries G, et al. Bacteriophages in gut samples from pediatric Crohn’s disease patients: metagenomic analysis using 454 pyrosequencing. Inflamm Bowel Dis. 2013;19:1598–608.PubMedCrossRef
132.
133.
McCole DF. IBD candidate genes and intestinal barrier regulation. Inflamm Bowel Dis. 2014;20:1829–49.PubMedCrossRef
134.
Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol. 2002;20:495–549.PubMedCrossRef
135.
Ruffolo C, Scarpa M, Faggian D, et al. Subclinical intestinal inflammation in patients with Crohn’s disease following bowel resection: a smoldering fire. J Gastrointest Surg. 2010;14:24–31.PubMedCrossRef
136.
Gassler N, Rohr C, Schneider A, et al. Inflammatory bowel disease is associated with changes of enterocytic junctions. Am J Physiol Gastrointest Liver Physiol. 2001;281:G216–28.PubMedCrossRef
137.
Zeissig S, Burgel N, Gunzel D, et al. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn’s disease. Gut. 2007;56:61–72.PubMedCrossRef
138.
Di Narzo AF, Brodmerkel C, Telesco SE, et al. High-throughput identification of the plasma proteomic signature of inflammatory bowel disease. J Crohns Colitis. 2019;13:462–71.PubMedCrossRef
139.
Katakura K, Lee J, Rachmilewitz D, et al. Toll-like receptor 9-induced type I IFN protects mice from experimental colitis. J Clin Investig. 2005;115:695–702.PubMedCrossRefPubMedCentral
140.
141.
Neurath MF, Finotto S, Glimcher LH. The role of Th1/Th2 polarization in mucosal immunity. Nat Med. 2002;8:567–73.PubMedCrossRef
142.
Vermeire S, Schreiber S, Petryka R, et al. Clinical remission in patients with moderate-to-severe Crohn’s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet. 2017;389:266–75.PubMedCrossRef
143.
Neurath MF. Current and emerging therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol. 2017;14:269–78.PubMedCrossRef
144.
Lichtenstein GR. Comprehensive review: antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment response. Therap Adv Gastroenterol. 2013;6:269–93.PubMedPubMedCentralCrossRef
145.
Friedrich M, Pohin M, Powrie F. Cytokine networks in the pathophysiology of inflammatory bowel disease. Immunity. 2019;50:992–1006.PubMedCrossRef
146.
Lu K, Knutson CG, Wishnok JS, et al. Serum metabolomics in a Helicobacter hepaticus mouse model of inflammatory bowel disease reveal important changes in the microbiome, serum peptides, and intermediary metabolism. J Proteome Res. 2012;11:4916–26.PubMedPubMedCentralCrossRef
147.
148.
Agouridis AP, Elisaf M, Milionis HJ. An overview of lipid abnormalities in patients with inflammatory bowel disease. Ann Gastroenterol. 2011;24:181–7.PubMedPubMedCentral
149.
Fan F, Mundra PA, Fang L, et al. Lipidomic profiling in inflammatory bowel disease: comparison between ulcerative colitis and Crohn’s disease. Inflamm Bowel Dis. 2015;21:1511–8.PubMedCrossRef
150.
Titz B, Gadaleta RM, Lo Sasso G, et al. Proteomics and lipidomics in inflammatory bowel disease research: from mechanistic insights to biomarker identification. Int J Mol Sci. 2018;19:2775.PubMedCentralCrossRef
151.
Scoville EA, Allaman MM, Brown CT, et al. Alterations in lipid, amino acid, and energy metabolism distinguish Crohn’s disease from ulcerative colitis and control subjects by serum metabolomic profiling. Metabolomics. 2018;14:17.PubMedCrossRef
152.
Murgia A, Hinz C, Liggi S, et al. Italian cohort of patients affected by inflammatory bowel disease is characterised by variation in glycerophospholipid, free fatty acids and amino acid levels. Metabolomics. 2018;14:140.PubMedCrossRef
153.
Contijoch EJ, Britton GJ, Yang C, et al. Gut microbiota density influences host physiology and is shaped by host and microbial factors. Elife. 2019;8:e40553.PubMedPubMedCentralCrossRef
154.
155.
156.
Waldschmitt N, Metwaly A, Fischer S, et al. Microbial signatures as a predictive tool in IBD-pearls and pitfalls. Inflamm Bowel Dis. 2018;24:1123–32.PubMedCrossRef
157.
Bercovici S, Meek C, Wexler Y, et al. Estimating genome-wide IBD sharing from SNP data via an efficient hidden Markov model of LD with application to gene mapping. Bioinformatics. 2010;26:i175–82.PubMedPubMedCentralCrossRef
158.
Fang K, Grisham MB, Kevil CG. Application of comparative transcriptional genomics to identify molecular targets for pediatric IBD. Front Immunol. 2015;6:165.PubMedPubMedCentralCrossRef
Metadata
Title
Integrating omics for a better understanding of Inflammatory Bowel Disease: a step towards personalized medicine
Authors
Manoj Kumar
Mathieu Garand
Souhaila Al Khodor
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2019
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-019-02174-1

Other articles of this Issue 1/2019

Journal of Translational Medicine 1/2019 Go to the issue

Research

Methylation and transcriptome analysis reveal lung adenocarcinoma-specific diagnostic biomarkers

Research

Novel nomograms to predict lymph node metastasis and liver metastasis in patients with early colon carcinoma

Review

Exploring the whole standard operating procedure for phage therapy in clinical practice

Research

Lupus serum IgG induces microglia activation through Fc fragment dependent way and modulated by B-cell activating factor

Research

Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm

Research

Cartilage progenitor cells combined with PHBV in cartilage tissue engineering

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits